drugset
drugset / Trial / NCT03911102

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

NCT03911102 ↗

Phase 2 Completed 63 enrolled Revance Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).

Timeline

Start
2019-03-11
Primary completion
2020-04-23
Completion
2020-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 12 unknown Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 24 unknown Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 36 unknown Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 48 unknown Intramuscular

Indications

eyelid disorder